Plant Name: Zanthoxylum bungeanum
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| TSHR; NPSR1; CXCR1; NMUR2; | |
| ADRA2C; ADRA2A; CNR1; DRD4; CNR2; | |
| ALPL; TDP1; PLA2G1B; FAAH; RECQL; P4HB; TERT; MTOR; PIK3R1; GLO1; MPO; AKR1B1; HSD17B10; ALOX15; ALDH1A1; HSD17B2; ALOX12; NOX4; PYGL; APEX1; POLB; | |
| ACHE; GAA; | |
| TRPV1; TRPA1; | |
| PKN1; AKT1; MET; CAMK2B; CSNK2A1; DAPK1; AXL; NEK2; FLT3; SRC; IGF1R; PTK2; AURKB; NEK6; GSK3B; CDK1; MAPK1; PIM1; NUAK1; ALK; KDR; | |
| CA5B; CA3; CA14; CA7; CA5A; CA12; CA9; CA4; CA6; CA2; CA1; | |
| PPARA; PPARG; PPARD; | |
| KDM4E; | |
| MAOA; ALOX5; XDH; | |
| MMP13; MMP3; MMP2; MMP9; | |
| BACE1; | |
| TLR2; | |
| STAT6; HIF1A; NFKB1; TP53; | |
| ABCC1; ABCG2; | |
| LMNA; FABP5; FABP2; FABP4; MAPT; FABP3; THPO; | |
| SMN1;SMN2; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Aspartic protease | BACE1 | Beta-secretase 1 | P56817 | CHEMBL4822 |
| ATP-binding cassette | ABCC1 | Multidrug resistance-associated protein 1 | P33527 | CHEMBL3004 |
| ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Cytochrome P450 family 2 | CYP2C8 | Cytochrome P450 2C8 | P10632 | CHEMBL3721 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | PIK3R1 | PI3-kinase p85-alpha subunit | P27986 | CHEMBL2506 |
| Enzyme_unclassified | GLO1 | Glyoxalase I | Q04760 | CHEMBL2424 |
| Enzyme_unclassified | MPO | Myeloperoxidase | P05164 | CHEMBL2439 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
| Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
| Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Enzyme_unclassified | PYGL | Liver glycogen phosphorylase | P06737 | CHEMBL2568 |
| Enzyme_unclassified | APEX1 | DNA-(apurinic or apyrimidinic site) lyase | P27695 | CHEMBL5619 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Enzyme_unclassified | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P05186 | CHEMBL5979 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | PLA2G1B | Phospholipase A2 group 1B | P04054 | CHEMBL4426 |
| Enzyme_unclassified | FAAH | Anandamide amidohydrolase | O00519 | CHEMBL2243 |
| Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
| Enzyme_unclassified | P4HB | Protein disulfide-isomerase | P07237 | CHEMBL5422 |
| Enzyme_unclassified | TERT | Telomerase reverse transcriptase | O14746 | CHEMBL2916 |
| Enzyme_unclassified | MTOR | Serine/threonine-protein kinase mTOR | P42345 | CHEMBL2842 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
| Lyase | CA5B | Carbonic anhydrase VB | Q9Y2D0 | CHEMBL3969 |
| Lyase | CA3 | Carbonic anhydrase III | P07451 | CHEMBL2885 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
| Metallo protease | MMP13 | Matrix metalloproteinase 13 | P45452 | CHEMBL280 |
| Metallo protease | MMP3 | Matrix metalloproteinase 3 | P08254 | CHEMBL283 |
| Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
| Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
| Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
| Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
| Nuclear hormone receptor subfamily 1 group C | PPARG | Peroxisome proliferator-activated receptor gamma | P37231 | CHEMBL235 |
| Nuclear hormone receptor subfamily 1 group C | PPARD | Peroxisome proliferator-activated receptor delta | Q03181 | CHEMBL3979 |
| Oxidoreductase | MAOA | Monoamine oxidase A | P21397 | CHEMBL1951 |
| Oxidoreductase | ALOX5 | Arachidonate 5-lipoxygenase | P09917 | CHEMBL215 |
| Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
| Peptide receptor (family A GPCR) | CXCR1 | Interleukin-8 receptor A | P25024 | CHEMBL4029 |
| Peptide receptor (family A GPCR) | NMUR2 | Neuromedin-U receptor 2 | Q9GZQ4 | CHEMBL1075144 |
| Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
| Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
| Protein Kinase | NUAK1 | NUAK family SNF1-like kinase 1 | O60285 | CHEMBL5784 |
| Protein Kinase | ALK | ALK tyrosine kinase receptor | Q9UM73 | CHEMBL4247 |
| Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
| Protein Kinase | PKN1 | Protein kinase N1 | Q16512 | CHEMBL3384 |
| Protein Kinase | AKT1 | Serine/threonine-protein kinase AKT | P31749 | CHEMBL4282 |
| Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
| Protein Kinase | CAMK2B | CaM kinase II beta | Q13554 | CHEMBL4121 |
| Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
| Protein Kinase | DAPK1 | Death-associated protein kinase 1 | P53355 | CHEMBL2558 |
| Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
| Protein Kinase | NEK2 | Serine/threonine-protein kinase NEK2 | P51955 | CHEMBL3835 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Kinase | SRC | Tyrosine-protein kinase SRC | P12931 | CHEMBL267 |
| Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
| Protein Kinase | PTK2 | Focal adhesion kinase 1 | Q05397 | CHEMBL2695 |
| Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
| Protein Kinase | NEK6 | Serine/threonine-protein kinase NEK6 | Q9HC98 | CHEMBL4309 |
| Protein Kinase | GSK3B | Glycogen synthase kinase-3 beta | P49841 | CHEMBL262 |
| Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
| Small molecule receptor (family A GPCR) | ADRA2C | Alpha-2c adrenergic receptor | P18825 | CHEMBL1916 |
| Small molecule receptor (family A GPCR) | ADRA2A | Alpha-2a adrenergic receptor | P08913 | CHEMBL1867 |
| Small molecule receptor (family A GPCR) | CNR1 | Cannabinoid CB1 receptor | P21554 | CHEMBL218 |
| Small molecule receptor (family A GPCR) | DRD4 | Dopamine D4 receptor | P21917 | CHEMBL219 |
| Small molecule receptor (family A GPCR) | CNR2 | Cannabinoid CB2 receptor | P34972 | CHEMBL253 |
| Toll-like and Il-1 receptors | TLR2 | Toll-like receptor 2 | O60603 | CHEMBL4163 |
| Transcription Factor | STAT6 | Signal transducer and activator of transcription 6 | P42226 | CHEMBL5401 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Transient receptor potential channel | TRPV1 | Vanilloid receptor | Q8NER1 | CHEMBL4794 |
| Transient receptor potential channel | TRPA1 | Transient receptor potential cation channel subfamily A member 1 | O75762 | CHEMBL6007 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
| Unclassified | FABP2 | Fatty acid binding protein intestinal | P12104 | CHEMBL4879 |
| Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
| Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
| Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 7.744E-11 | 2.012E-08 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP3A4, NOX4 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 7.457E-10 | 1.640E-07 | ALOX12, ALOX15, ALOX5, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP3A4, XDH |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 8.729E-10 | 1.845E-07 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8 |
| MF | GO:0005488; binding | GO:0005524; ATP binding | 1.234E-09 | 2.511E-07 | ABCC1, ABCG2, AKT1, ALK, AURKB, AXL, CAMK2B, CDK1, CSNK2A1, DAPK1, FLT3, GSK3B, IGF1R, KDR, MAPK1, MET, MTOR, NEK2, NEK6, NUAK1, PIM1, PKN1, PTK2, PYGL, RECQL, SRC, TP53, TRPV1 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 1.320E-09 | 2.662E-07 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP3A4, MPO, NOX4, SRC |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 1.652E-09 | 3.295E-07 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C8, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0071456; cellular response to hypoxia | 3.704E-09 | 6.136E-07 | AKT1, HIF1A, LMNA, MTOR, P4HB, PPARD, SRC, TERT, TP53 |
| BP | GO:0008152; metabolic process | GO:0018107; peptidyl-threonine phosphorylation | 7.312E-09 | 1.137E-06 | AKT1, CAMK2B, CDK1, CSNK2A1, GSK3B, MAPK1, MTOR, PKN1 |
| BP | GO:0008152; metabolic process | GO:0006691; leukotriene metabolic process | 1.165E-08 | 1.761E-06 | ABCC1, ALOX12, ALOX15, ALOX5, PLA2G1B, TLR2 |
| MF | GO:0003824; catalytic activity | GO:0004674; protein serine/threonine kinase activity | 1.334E-08 | 1.924E-06 | AKT1, ALK, AURKB, CAMK2B, CDK1, CSNK2A1, DAPK1, GSK3B, MAPK1, MTOR, NEK2, NEK6, NUAK1, PIM1, PKN1 |
| BP | GO:0008152; metabolic process | GO:0018105; peptidyl-serine phosphorylation | 1.549E-08 | 2.177E-06 | AKT1, AURKB, CAMK2B, CDK1, GSK3B, MAPK1, MTOR, NEK6, PKN1, SRC |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 3.690E-08 | 4.783E-06 | CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, GLO1, MMP13, MMP2, MMP3, MMP9, PPARA, PPARD, PPARG, TP53 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 6.735E-08 | 7.927E-06 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8 |
| BP | Unclassified; | GO:0032844; regulation of homeostatic process | 1.776E-07 | 1.887E-05 | ADRA2A, AURKB, CA2, CA7, CNR1, HIF1A, KDR, MAPK1, NEK2, NPSR1, PLA2G1B, SRC, TRPA1, TRPV1 |
| BP | GO:0009987; cellular process | GO:0071407; cellular response to organic cyclic compound | 3.005E-07 | 3.086E-05 | AKT1, ALPL, APEX1, CYP1A1, CYP1B1, FLT3, MAPK1, NFKB1, NOX4, PPARG, SRC, TRPV1 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 3.375E-07 | 3.434E-05 | CYP1A2, CYP2C19, CYP2C8, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 5.529E-07 | 5.281E-05 | CYP1A2, CYP2C8, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0070301; cellular response to hydrogen peroxide | 7.740E-07 | 7.111E-05 | AKR1B1, APEX1, AXL, CDK1, CYP1B1, STAT6 |
| BP | GO:0065007; biological regulation | GO:0032148; activation of protein kinase B activity | 8.726E-07 | 7.851E-05 | ADRA2A, ADRA2C, AKT1, MTOR, SRC |
| BP | GO:0009987; cellular process | GO:0051897; positive regulation of protein kinase B signaling | 1.331E-06 | 1.159E-04 | AXL, MET, MTOR, NOX4, PIK3R1, PTK2, SRC, THPO |
| BP | Unclassified; | GO:0044236; multicellular organism metabolic process | 1.382E-06 | 1.190E-04 | HIF1A, MMP13, MMP2, MMP3, MMP9, PLA2G1B, TRPV1 |
| MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 1.377E-06 | 1.190E-04 | CYP1A1, CYP2C8, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0030168; platelet activation | 1.774E-06 | 1.452E-04 | ADRA2A, ADRA2C, AKT1, AXL, MAPK1, PIK3R1, SRC |
| BP | GO:0065007; biological regulation | GO:0042593; glucose homeostasis | 1.867E-06 | 1.511E-04 | ADRA2A, AKT1, CNR1, HIF1A, NOX4, PIK3R1, PPARG, PYGL |
| BP | GO:0050896; response to stimulus | GO:0032496; response to lipopolysaccharide | 1.907E-06 | 1.529E-04 | ALPL, AXL, CNR1, CNR2, CYP1A1, CYP1A2, MPO, NFKB1, PPARD, SRC |
| BP | GO:0008152; metabolic process | GO:0002933; lipid hydroxylation | 2.744E-06 | 2.104E-04 | CYP1A1, CYP2C8, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 2.744E-06 | 2.104E-04 | CYP1A2, CYP2C19, CYP3A4 |
| BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 2.879E-06 | 2.192E-04 | AURKB, CA2, CA7, CNR1, HIF1A, MAPK1, NEK2, NPSR1, PLA2G1B |
| BP | GO:0050896; response to stimulus | GO:0055093; response to hyperoxia | 3.936E-06 | 2.885E-04 | CYP1A1, POLB, PPARG, TP53 |
| MF | GO:0005488; binding | GO:0051379; epinephrine binding | 7.624E-06 | 5.237E-04 | ADRA2A, ADRA2C, DRD4 |
| BP | GO:0008152; metabolic process | GO:0019433; triglyceride catabolic process | 8.186E-06 | 5.536E-04 | FABP2, FABP3, FABP4, FABP5 |
| BP | Unclassified; | GO:2000021; regulation of ion homeostasis | 1.355E-05 | 8.728E-04 | CA2, CA7, KDR, NPSR1, PLA2G1B, SRC, TRPA1, TRPV1 |
| BP | GO:0008152; metabolic process | GO:0051974; negative regulation of telomerase activity | 1.621E-05 | 1.032E-03 | PPARG, SRC, TP53 |
| BP | GO:0032502; developmental process | GO:0045597; positive regulation of cell differentiation | 1.630E-05 | 1.035E-03 | ADRA2C, AKT1, AXL, CA2, CAMK2B, CNR1, HIF1A, KDR, MAPT, MTOR, NFKB1, PPARD, PPARG, TERT, THPO, TLR2 |
| BP | GO:0009987; cellular process | GO:0043065; positive regulation of apoptotic process | 1.688E-05 | 1.065E-03 | AKT1, CNR1, CYP1B1, DAPK1, GSK3B, MAPT, MMP9, NOX4, PPARG, SRC, TP53, TRPV1, XDH |
| BP | GO:0009987; cellular process | GO:0071276; cellular response to cadmium ion | 1.988E-05 | 1.226E-03 | AKT1, CYP1A2, MAPK1, MMP9 |
| MF | GO:0005488; binding | GO:0051879; Hsp90 protein binding | 2.263E-05 | 1.365E-03 | CSNK2A1, HIF1A, KDR, MAPT |
| BP | GO:0009987; cellular process | GO:0031334; positive regulation of protein complex assembly | 2.386E-05 | 1.432E-03 | ALOX15, GSK3B, MAPT, MET, MMP3, MTOR, SRC, TP53 |
| BP | GO:0009987; cellular process | GO:0006286; base-excision repair, base-free sugar-phosphate removal | 2.707E-05 | 1.580E-03 | APEX1, POLB |
| BP | GO:0008152; metabolic process | GO:2001303; lipoxin A4 biosynthetic process | 2.707E-05 | 1.580E-03 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0047977; hepoxilin-epoxide hydrolase activity | 2.707E-05 | 1.580E-03 | ALOX12, ALOX15 |
| BP | GO:0008152; metabolic process | GO:0045913; positive regulation of carbohydrate metabolic process | 2.840E-05 | 1.654E-03 | AKT1, HIF1A, NFKB1, PPARA, SRC |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 2.950E-05 | 1.699E-03 | CYP1A2, CYP2C8, CYP3A4 |
| BP | GO:0065007; biological regulation | GO:0098771; inorganic ion homeostasis | 3.027E-05 | 1.734E-03 | ABCG2, CA12, CA2, CA7, DRD4, HIF1A, MAPK1, NMUR2, NPSR1, PLA2G1B, TP53, TRPA1, TRPV1 |
| BP | GO:0050896; response to stimulus | GO:0050728; negative regulation of inflammatory response | 3.125E-05 | 1.776E-03 | CNR2, CYP19A1, NFKB1, PPARA, PPARD, PPARG |
| BP | GO:0008152; metabolic process | GO:0008610; lipid biosynthetic process | 3.162E-05 | 1.788E-03 | ACHE, AKR1B1, ALOX12, ALOX15, CSNK2A1, CYP19A1, CYP1A1, CYP3A4, HSD17B2, PIK3R1, PLA2G1B, PPARD |
| BP | GO:0009987; cellular process | GO:0048010; vascular endothelial growth factor receptor signaling pathway | 3.749E-05 | 2.067E-03 | AXL, KDR, PIK3R1, PTK2, SRC |
| BP | Unclassified; | GO:0044243; multicellular organismal catabolic process | 4.009E-05 | 2.182E-03 | MMP13, MMP2, MMP3, MMP9, PLA2G1B |
| BP | GO:0065007; biological regulation | GO:0030003; cellular cation homeostasis | 4.031E-05 | 2.184E-03 | ABCG2, CA2, CA7, DRD4, HIF1A, MAPK1, NMUR2, NPSR1, PLA2G1B, TP53, TRPA1, TRPV1 |
| BP | GO:0022414; reproductive process | GO:0060135; maternal process involved in female pregnancy | 4.073E-05 | 2.184E-03 | AKR1B1, AKT1, CNR1, MTOR |
| MF | GO:0005488; binding | GO:0001221; transcription cofactor binding | 4.073E-05 | 2.184E-03 | NEK6, PPARA, TERT, TP53 |
| BP | GO:0008152; metabolic process | GO:0045862; positive regulation of proteolysis | 4.192E-05 | 2.232E-03 | ADRA2A, AKT1, CDK1, DAPK1, GSK3B, MAPT, PPARG, PTK2, SRC, XDH |
| BP | GO:0032502; developmental process | GO:0031100; animal organ regeneration | 4.870E-05 | 2.537E-03 | AXL, CDK1, CSNK2A1, FLT3, PPARG |
| MF | GO:0005488; binding | GO:0051219; phosphoprotein binding | 4.870E-05 | 2.537E-03 | MAPK1, MTOR, PIK3R1, SRC, TRPV1 |
| BP | GO:0050896; response to stimulus | GO:0042060; wound healing | 5.187E-05 | 2.651E-03 | ALOX15, MTOR, PPARA, PPARD, TP53 |
| BP | GO:0009987; cellular process | GO:1900034; regulation of cellular response to heat | 5.519E-05 | 2.808E-03 | CAMK2B, GSK3B, MAPK1, MAPT, MTOR |
| MF | GO:0005488; binding | GO:0046982; protein heterodimerization activity | 5.779E-05 | 2.923E-03 | ADRA2A, ADRA2C, AXL, HIF1A, NFKB1, P4HB, PIK3R1, PPARD, PPARG, TLR2, TP53 |
| BP | GO:0050896; response to stimulus | GO:0070542; response to fatty acid | 6.233E-05 | 3.120E-03 | AKT1, FABP3, PPARG, SRC, TLR2 |
| MF | Unclassified; | GO:0032403; protein complex binding | 6.601E-05 | 3.282E-03 | ACHE, ADRA2A, APEX1, FLT3, IGF1R, KDR, MMP13, MMP9, P4HB, PIK3R1, PPARA, SRC, TLR2, TSHR |
| BP | GO:0002376; immune system process | GO:0002684; positive regulation of immune system process | 6.800E-05 | 3.350E-03 | AKT1, AXL, CA2, CNR1, HIF1A, MAPK1, MMP2, NFKB1, PIK3R1, PLA2G1B, PTK2, SRC, STAT6, THPO, TLR2, TP53 |
| BP | GO:0008152; metabolic process | GO:0019372; lipoxygenase pathway | 7.395E-05 | 3.590E-03 | ALOX12, ALOX15, ALOX5 |
| BP | GO:0032501; multicellular organismal process | GO:0050968; detection of chemical stimulus involved in sensory perception of pain | 8.094E-05 | 3.782E-03 | TRPA1, TRPV1 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 8.094E-05 | 3.782E-03 | CA2, CA7 |
| BP | GO:0032501; multicellular organismal process | GO:0050955; thermoception | 8.094E-05 | 3.782E-03 | TRPA1, TRPV1 |
| MF | GO:0005215; transporter activity | GO:0097603; temperature-gated ion channel activity | 8.094E-05 | 3.782E-03 | TRPA1, TRPV1 |
| MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 8.094E-05 | 3.782E-03 | CYP1A1, CYP3A4 |
| MF | GO:0060089; molecular transducer activity | GO:0004949; cannabinoid receptor activity | 8.094E-05 | 3.782E-03 | CNR1, CNR2 |
| MF | GO:0003824; catalytic activity | GO:0004052; arachidonate 12-lipoxygenase activity | 8.094E-05 | 3.782E-03 | ALOX12, ALOX15 |
| MF | GO:0060089; molecular transducer activity | GO:0004938; alpha2-adrenergic receptor activity | 8.094E-05 | 3.782E-03 | ADRA2A, ADRA2C |
| MF | GO:0003824; catalytic activity | GO:0051120; hepoxilin A3 synthase activity | 8.094E-05 | 3.782E-03 | ALOX12, ALOX15 |
| BP | Unclassified; | GO:0044259; multicellular organismal macromolecule metabolic process | 8.809E-05 | 4.072E-03 | HIF1A, MMP13, MMP2, MMP3, MMP9 |
| BP | GO:0009987; cellular process | GO:0090199; regulation of release of cytochrome c from mitochondria | 8.898E-05 | 4.075E-03 | AKT1, LMNA, MMP9, TP53 |
| BP | GO:0002376; immune system process | GO:0001774; microglial cell activation | 8.946E-05 | 4.075E-03 | MAPT, TLR2, TRPV1 |
| BP | GO:0065007; biological regulation | GO:1904355; positive regulation of telomere capping | 8.946E-05 | 4.075E-03 | AURKB, MAPK1, NEK2 |
| BP | GO:0050896; response to stimulus | GO:0033189; response to vitamin A | 8.946E-05 | 4.075E-03 | CYP1A1, PPARD, PPARG |
| MF | GO:0003824; catalytic activity | GO:0035173; histone kinase activity | 8.946E-05 | 4.075E-03 | AURKB, CDK1, PKN1 |
| BP | GO:0065007; biological regulation | GO:0000187; activation of MAPK activity | 1.054E-04 | 4.706E-03 | ALK, CDK1, DRD4, MAPK1, PKN1, PLA2G1B |
| BP | GO:0008152; metabolic process | GO:0038083; peptidyl-tyrosine autophosphorylation | 1.057E-04 | 4.706E-03 | IGF1R, KDR, PTK2, SRC |
| BP | Unclassified; | GO:1905953; negative regulation of lipid localization | 1.057E-04 | 4.706E-03 | AKT1, NFKB1, PPARA, PPARG |
| BP | GO:0032501; multicellular organismal process | GO:0048714; positive regulation of oligodendrocyte differentiation | 1.069E-04 | 4.743E-03 | MTOR, PPARG, TLR2 |
| BP | GO:0008152; metabolic process | GO:0051000; positive regulation of nitric-oxide synthase activity | 1.069E-04 | 4.743E-03 | AKT1, HIF1A, TERT |
| BP | GO:0050896; response to stimulus | GO:0043279; response to alkaloid | 1.152E-04 | 5.048E-03 | CNR1, MTOR, PPARG, TP53, TRPV1 |
| BP | GO:0050896; response to stimulus | GO:0009410; response to xenobiotic stimulus | 1.182E-04 | 5.157E-03 | CNR1, CNR2, DRD4, MTOR, PPARG, TP53 |
| CC | GO:0044464; cell part | GO:0005829; cytosol | 1.181E-04 | 5.157E-03 | AKR1B1, AKT1, ALDH1A1, ALOX12, ALOX15, ALOX5, AURKB, CA1, CA2, CA3, CA7, CAMK2B, CDK1, CSNK2A1, FABP2, FABP3, FABP4, FABP5, FLT3, GLO1, GSK3B, HIF1A, LMNA, MAPK1, MAPT, MTOR, NEK2, NEK6, NFKB1, PIK3R1, PIM1, PKN1, PLA2G1B, PPARG, PTK2, PYGL, SMN1, SMN2, SRC, STAT6, TP53, TRPV1, XDH |
| BP | GO:0048511; rhythmic process | GO:0048511; rhythmic process | 1.227E-04 | 5.291E-03 | AXL, CSNK2A1, DRD4, GSK3B, PPARA, PPARG, SRC, TP53 |
| MF | Unclassified; | GO:0004872; receptor activity | 1.385E-04 | 5.912E-03 | ADRA2A, ADRA2C, ALK, AXL, CNR1, CNR2, CXCR1, DRD4, FLT3, IGF1R, KDR, MET, NMUR2, NPSR1, PPARA, PPARD, PPARG, TLR2, TRPV1, TSHR |
| CC | GO:0043226; organelle | GO:0005654; nucleoplasm | 1.484E-04 | 6.264E-03 | AKR1B1, AKT1, ALOX5, APEX1, AURKB, CAMK2B, CDK1, CSNK2A1, FABP5, GSK3B, HIF1A, LMNA, MAPK1, MTOR, NEK2, NEK6, NFKB1, NUAK1, PIM1, PKN1, POLB, PPARA, PPARD, PPARG, RECQL, SMN1, SMN2, SRC, STAT6, TERT, TP53 |
| BP | GO:0065007; biological regulation | GO:0032431; activation of phospholipase A2 activity | 1.613E-04 | 6.691E-03 | NMUR2, PLA2G1B |
| BP | GO:0065007; biological regulation | GO:0035625; epidermal growth factor-activated receptor transactivation by G-protein coupled receptor signaling pathway | 1.613E-04 | 6.691E-03 | ADRA2A, ADRA2C |
| BP | GO:0009987; cellular process | GO:0032811; negative regulation of epinephrine secretion | 1.613E-04 | 6.691E-03 | ADRA2A, ADRA2C |
| BP | GO:0009987; cellular process | GO:0038171; cannabinoid signaling pathway | 1.613E-04 | 6.691E-03 | CNR1, CNR2 |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 1.613E-04 | 6.691E-03 | CYP1A1, CYP1A2 |
| BP | GO:0009987; cellular process | GO:0051493; regulation of cytoskeleton organization | 1.613E-04 | 6.691E-03 | ALOX15, GSK3B, MAPK1, MAPT, MET, MTOR, NEK2, NOX4, PIK3R1, PTK2 |
| MF | GO:0005488; binding | GO:0043621; protein self-association | 1.822E-04 | 7.415E-03 | ACHE, FLT3, PPARG, TP53 |
| BP | GO:0008152; metabolic process | GO:1902895; positive regulation of pri-miRNA transcription from RNA polymerase II promoter | 1.988E-04 | 7.968E-03 | HIF1A, TERT, TP53 |
| BP | GO:0008283; cell proliferation | GO:1904707; positive regulation of vascular smooth muscle cell proliferation | 1.988E-04 | 7.968E-03 | MMP2, MMP9, TERT |
| BP | GO:0022610; biological adhesion | GO:0001952; regulation of cell-matrix adhesion | 2.064E-04 | 8.203E-03 | GSK3B, KDR, PIK3R1, PTK2, SRC |
| BP | GO:0009987; cellular process | GO:2001237; negative regulation of extrinsic apoptotic signaling pathway | 2.064E-04 | 8.203E-03 | AKT1, DAPK1, LMNA, SRC, TERT |
| BP | GO:0002376; immune system process | GO:0043312; neutrophil degranulation | 2.155E-04 | 8.499E-03 | ALOX5, CXCR1, FABP5, GAA, MAPK1, MMP9, MPO, NFKB1, PYGL, TLR2 |
| BP | GO:0008152; metabolic process | GO:0031331; positive regulation of cellular catabolic process | 2.273E-04 | 8.824E-03 | ADRA2A, AKT1, CDK1, DAPK1, GSK3B, HIF1A, KDR, PPARA, PTK2 |
| BP | GO:0051179; localization | GO:0050482; arachidonic acid secretion | 2.277E-04 | 8.824E-03 | DRD4, NMUR2, PLA2G1B |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 2.277E-04 | 8.824E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0002376; immune system process | GO:0048534; hematopoietic or lymphoid organ development | 2.456E-04 | 9.466E-03 | FLT3, HIF1A, KDR, MAPK1, PKN1, POLB |
| BP | GO:0051179; localization | GO:0032368; regulation of lipid transport | 2.466E-04 | 9.487E-03 | AKT1, CYP19A1, NFKB1, PPARA, PPARG |
| BP | GO:0050896; response to stimulus | GO:0035902; response to immobilization stress | 2.593E-04 | 9.802E-03 | CYP1A1, CYP1A2, PPARG |
| MF | GO:0003824; catalytic activity | GO:0009055; electron transfer activity | 2.575E-04 | 9.802E-03 | AKR1B1, CYP19A1, CYP1A2, NOX4, XDH |
| MF | Unclassified; | GO:0099600; transmembrane receptor activity | 2.593E-04 | 9.802E-03 | ADRA2A, ADRA2C, ALK, AXL, CNR1, CNR2, CXCR1, DRD4, FLT3, IGF1R, KDR, MET, NMUR2, NPSR1, PPARG, TRPV1, TSHR |
| BP | GO:0008152; metabolic process | GO:0051122; hepoxilin biosynthetic process | 2.679E-04 | 9.889E-03 | ALOX12, ALOX15 |
| BP | Unclassified; | GO:0051534; negative regulation of NFAT protein import into nucleus | 2.679E-04 | 9.889E-03 | GSK3B, MTOR |
| BP | GO:0051179; localization | GO:0010891; negative regulation of sequestering of triglyceride | 2.679E-04 | 9.889E-03 | PPARA, PPARG |
| MF | GO:0005488; binding | GO:0051380; norepinephrine binding | 2.679E-04 | 9.889E-03 | ADRA2A, DRD4 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 6.113E-23 | 1.331E-18 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 3.033E-16 | 4.718E-13 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 2.197E-15 | 2.392E-12 | CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3 |
| C00-D49: Neoplasms | Metastasis | C00-C97 | AXL |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | TLR2 |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT; CNR1; PPARD |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET; FAAH |
| A00-B99: Certain infectious and parasitic diseases | Lymphatic filariasis | B74 | ALOX5 |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | ADRA2C; CNR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | PPARD |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Organ rejection | D89.8, T86 | MTOR |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | ALOX5; MMP13; MMP3; MMP2 |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | ALOX5; PPARD |
| I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | PLA2G1B |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | PLA2G1B; ALOX5; ALOX5; TRPV1; ADRA2C |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PLA2G1B; ABCC1; ALOX5 |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; CA1 |
| C00-D49: Neoplasms | Liver cancer | C22 | TERT; IGF1R; KDR |
| A00-B99: Certain infectious and parasitic diseases | Leishmaniasis | B55.0 | PLA2G1B |
| C00-D49: Neoplasms | Leukemia | C90-C95 | AKT1; FLT3 |
| C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Contact dermatitis | L23, L24, L25 | PLA2G1B |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; AXL; MTOR; IGF1R; IGF1R; KDR |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; KDR |
| C00-D49: Neoplasms | Hematologic malignancies | C81-C86 | AKT1 |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | SRC; AURKB; TP53 |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3 |
| C00-D49: Neoplasms | Osteosarcoma | C40-C41 | SRC; GSK3B |
| C00-D49: Neoplasms | Overactive bladder disorder | C67, N32.81 | TRPV1; TRPV1 |
| C00-D49: Neoplasms | Chronic myelogenous leukaemia | C92.1 | SRC |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | MPO; ALOX5 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pathological pain | R52, G89 | TRPV1 |
| I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | SRC; CNR1 |
| I00-I99: Diseases of the circulatory system | Ischemic stroke | I61-I63 | MMP3 |
| C00-D49: Neoplasms | Gastric cancer | C16 | KDR; KDR |
| H00-H59: Diseases of the eye and adnexa | Ocular inflammation | H16.229 | TERT; PPARG |
| H00-H59: Diseases of the eye and adnexa | Ocular disease | H00-H59 | ADRA2C |
| C00-D49: Neoplasms | Ocular cancer | C69 | APEX1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | IGF1R |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1 |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE |
| K00-K95: Diseases of the digestive system | Peptic ulcer | K25-K27 | ADRA2C |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | MPO; MAOA; ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | MMP13; MTOR; ACHE; TRPV1; TRPV1; IGF1R; CDK1; ADRA2C; ADRA2A; TRPA1; FAAH; CNR1; CNR2 |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | AKT1; TERT; MTOR; FLT3; MMP2; TLR2; KDR |
| C00-D49: Neoplasms | CLL | NA | FLT3 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT; ACHE |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PPARG; CNR2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ALOX5 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of corticosteroid responsive dermatoses | L20-L30 | PLA2G1B |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | MPO; PLA2G1B; ALOX5; MMP13; MTOR; FAAH; CNR2 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp | L20-L30 | PLA2G1B |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Attention deficit hyperactivity disorder | F90 | ADRA2A |
| NA: NA | Upper abdominal bloating | NA | ACHE |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | CNR1 |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | AKT1; MTOR; CA9; HIF1A |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Fibromyalgia | M79.7 | ADRA2C |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | ALOX5 |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3 |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | DRD4; CNR1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | ALOX5; FLT3 |
| C00-D49: Neoplasms | Prostate cancer | C61 | TERT; FLT3; TLR2 |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1 |
| C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR |
| I00-I99: Diseases of the circulatory system | Myocardial infarction | I21, I22 | MMP3 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Myocardial reperfusion injury | T86.4 | AKT1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | TLR2; KDR |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1 |
| C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Genetic disease | Q00-Q99 | ALPL |
| I00-I99: Diseases of the circulatory system | Hypotension | I95 | ADRA2C |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
| C00-D49: Neoplasms | Renal cancer | C64 | MTOR; CA9; KDR |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MTOR; MAPK1 |
| J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | ALOX5 |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
| C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Nicotine dependence | F17 | PPARG; CNR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | MAOA; TRPV1; CNR1; CNR2 |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ADRA2C; NPSR1 |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Lipid metabolism disorder | E75-E78 | CNR1 |
| A00-B99: Certain infectious and parasitic diseases | Infections disease | A00-B99 | MPO |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Immune disorder | D80-D89 | CNR2 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Radiation sickness | T66 | TLR2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | ADRA2C |
| C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET |
| C00-D49: Neoplasms | Breast cancer | C50 | TERT; FLT3; FLT3; CA9; IGF1R; CYP19A1; CDK1; KDR; KDR; KDR |
| C00-D49: Neoplasms | Mesothelioma | C45 | PTK2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | PPARD |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | DRD4; CNR1 |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | ACHE; CA4; CA2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; CNR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | CAMK2B; AKR1B1; PLA2G1B; ALOX5; MMP3; CNR2 |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; PPARG |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chemotherapy-induced nausea | R11 | CNR1 |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | FLT3; IGF1R; MMP9; TP53; KDR |
| C00-D49: Neoplasms | Colon cancer | C50 | ALPL; FLT3 |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | PTK2; TP53 |
| C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR |
| G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2 |
| C00-D49: Neoplasms | Solid tumors | NA | MTOR |
| C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | PLA2G1B; ALOX5 |
| G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | MPO |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Musculoskeletal pain | R52, G89 | TRPV1 |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE |
| I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR |
| A00-B99: Certain infectious and parasitic diseases | Anthelmintic | B89 | ALPL |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Contusion | S36.220S | ADRA2C |
| H00-H59: Diseases of the eye and adnexa | Corneal ulcers | H16.0 | MMP3 |
| NA: NA | Coronary artery restenosis | NA | MTOR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sexual dysfunction | F52 | ADRA2A |
| C00-D49: Neoplasms | Melanoma | C43 | TERT; TLR2; KDR; KDR |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Nerve injury | T14.4 | PLA2G1B |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | MAOA |
| K00-K95: Diseases of the digestive system | Gastroesophageal reflux disease | K21 | TRPV1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | SRC; CNR2 |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT; ACHE |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | ADRA2C; CA4; CA4 |
| C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; KDR |
| C00-D49: Neoplasms | Advanced kidney cancer | C64 | MTOR |
| C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | ALOX5 |
| J00-J99: Diseases of the respiratory system | Throat irritation | J39.2 | TRPA1 |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR; KDR |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; ADRA2C |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE |
| C00-D49: Neoplasms | Sarcoma | C81-C86 | MTOR |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | SRC; CYP19A1 |
| I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | GAA |
| A00-B99: Certain infectious and parasitic diseases | Postherpetic neuralgia | B02.2, G44.847, G53.0 | TRPV1; CNR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; ABCC1; ABCC1; XDH; PPARG |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Transplant rejection | D89.8, T86 | MTOR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Endocrine disease | E00-E35 | CNR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| NA: NA | Edema | NA | CA2 |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TERT; FLT3; FLT3; AURKB; TP53; TP53 |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3 |
| G00-G99: Diseases of the nervous system G00-G99 | Acute migraine | G43 | TRPV1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Acute or chronic pain | R52, G89 | TRPV1 |
| J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | ALOX5 |
| A00-B99: Certain infectious and parasitic diseases | Dutch elm disease | B81-B83 | MTOR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dyslipidaemias | E78 | PPARD; PPARD |
| NA: NA | Dyslipidemia | NA | PPARD |
| C00-D49: Neoplasms | Ovarian cancer | C56 | TERT; MMP2; CNR1; KDR; KDR; KDR; KDR |
| K00-K95: Diseases of the digestive system | Non-alcoholic fatty liver disease | K76.0 | PPARG; PPARD |
| L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | ALOX5; TRPV1; CNR2 |
| A00-B99: Certain infectious and parasitic diseases | Visceral leishmaniasis | B55.0 | PLA2G1B |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | MAOA |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | MAOA; MAOA; FAAH |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anorexia | F50.0-F50.1 | CNR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CAMK2B; MAOA; ACHE; FAAH; CYP3A4 |
| K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | PPARG; PPARD |
| C00-D49: Neoplasms | Tumors | C00-D48 | TERT |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1; PPARG; PPARG; CNR1; PPARD |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2; KDR; KDR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Erythema | L51-L54 | ADRA2C |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | MAOA |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE |
| NA: NA | Esophagus sensitivity | NA | TRPV1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Anesthesia | R20.0 | FAAH |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3 |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MTOR; MMP9 |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE |
| C00-D49: Neoplasms | Glioma | C71 | KDR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | MMP2 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R |
| H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | MAOA; ADRA2C |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ALOX5 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | AKR1B1; GSK3B; PPARG; CNR1; CNR1; CNR1 |
| C00-D49: Neoplasms | AML | NA | FLT3; KDR |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | PLA2G1B; ADRA2C |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAOA; MAPT; ACHE; ACHE; ACHE; GSK3B; ADRA2C; PPARG; PPARG |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | PLA2G1B; ALOX5 |
| C00-D49: Neoplasms | Bladder cancer | C67 | MTOR; CYP19A1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE |
| C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR |
| I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | XDH; ADRA2C |
| A00-B99: Certain infectious and parasitic diseases | HCV infection | B17.1, B18.2 | MMP3 |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | AKR1B1; TERT; TP53; KDR; KDR |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | AKT1; MET; MTOR; FLT3; CA9; MMP2; SRC; IGF1R; PTK2; AURKB; HIF1A; MAPK1; MMP9; TLR2; TP53; KDR; KDR; KDR |
| C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cough | R05 | TRPV1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | MAOA; ADRA2C |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3 |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | TERT; SRC |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR |
| C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2 |
| N00-N99: Diseases of the genitourinary system | Urinary incontinence | N39.3, N39.4, R32 | TRPV1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Erectile dysfunction | F52.2, N48.4 | DRD4 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | ADRA2C; PPARG; CNR1; CNR1; CNR1; CNR1; CNR1; CNR1; PPARD; PPARD |
| C00-D49: Neoplasms | Non-hodgkin's lymphoma | C85 | MTOR |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | MMP2; KDR |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| C00-D49: Neoplasms | Cancer | C00-C96 | AKT1; MET; CSNK2A1; MTOR; FLT3; FLT3; CA9; MMP2; ACHE; SRC; IGF1R; PTK2; GSK3B; HIF1A; CDK1; MAPK1; MMP9; NFKB1; PIM1; TLR2; TP53; CA1; KDR |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3 |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3 |
| C00-D49: Neoplasms | Glioblastoma multiforme | C71 | SRC |
| NA: NA | GIST | NA | FLT3 |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | AKR1B1; ACHE; ADRA2C; CA1; CA1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1; TRPV1 |
| C00-D49: Neoplasms | Multiple myeloma | C90 | TERT; MTOR; MTOR; SRC; IGF1R |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | PPARG; CNR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Male sexual disorders | F52 | ADRA2C |
| C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R |